Inflammation of the central nervous system (CNS) is important in many human diseases, and is regulated by a multitude of factors, including the cytokine interferon-gamma (IFNgamma). The importance of IFNgamma is highlighted in experimental autoimmune encephalomyelitis (EAE), an animal model of CNS inflammation. Mice lacking IFNgamma show exaggerated disease, with a different pattern of chemokine expression than the wild-type. We administered IFNgamma to the CNS using intrathecal injection of a replication-defective adenoviral vector to ask about direct actions of IFNgamma on chemokine expression without the confounding factors present during CNS inflammation. AdIFNgamma induced expression of CXCL10 and CCL5, two chemokines strikingly absent in Ifng-/- EAE. Chemokine expression was not associated with inflammation, though when an infectious stimulus was administered, an influx of immune cells to the CNS was seen. Using AdIFNgamma to restore IFNgamma to Ifng-/- mice with EAE had a disease-limiting effect. We used vectors encoding CXCL10 or CCL5, to replace these chemokines which are absent during Ifng-/- EAE, attempting to modulate the disease into a form resembling that of the wild-type. AdCCL5 treatment showed a mild reduction in EAE severity in the Ifng-/-, though AdCXCL10 treatment had no effect. A principal inducer of IFNgamma is interleukin-18 (IL 18), and IFNgamma induces IL18-binding protein (IL18bp) which inhibits IL18, establishing a negative feedback loop. We found that ILl8bp expression is upregulated in wild-type mice with EAE, but not in the Ifng-/-, suggesting that the exaggerated disease of the Ifng -/- may be due in part to unrestrained actions of ILI8. Treatment with a vector encoding IL18bp (AdIL18bp) significantly inhibited EAE, without restricting immune cell entry to the CNS. Cytokine expression was shifted away from a pattern favouring Th17 development. AdIL18bp treatment inhibited EAE in Ifng-/- mice, indicating that IFNgamma was not required for this activity. We used a vector encoding M3, a chemokine-binding protein derived from MHV-68, to reduce EAE severity, showing the first use of a viral chemokine-binding protein in EAE.
Identifer | oai:union.ndltd.org:LACETR/oai:collectionscanada.gc.ca:QMM.115699 |
Date | January 2008 |
Creators | Millward, Jason Michael, 1976- |
Publisher | McGill University |
Source Sets | Library and Archives Canada ETDs Repository / Centre d'archives des thèses électroniques de Bibliothèque et Archives Canada |
Language | English |
Detected Language | English |
Type | Electronic Thesis or Dissertation |
Format | application/pdf |
Coverage | Doctor of Philosophy (Division of Neuroscience.) |
Rights | All items in eScholarship@McGill are protected by copyright with all rights reserved unless otherwise indicated. |
Relation | alephsysno: 003135279, proquestno: AAINR66562, Theses scanned by UMI/ProQuest. |
Page generated in 7.5528 seconds